Daily Literature Update
Evaluation of Pharmacokinetics of Lebrikizumab in Healthy Individuals After Subcutaneous Administration Using a Prefilled Syringe or Autoinjector in a Phase 1 Randomized Study
Datta-Mannan A, Moser B, Xu W, Jackson K, Witcher J, Armstrong AW, Blauvelt A, Lio PA. Clin Ther. 2025 Jan;47(1):55-61. PMID: 39638723.
Introduction
Lebrikizumab targets interleukin-13 and is approved for moderate-to-severe atopic dermatitis. This study evaluates pharmacokinetics and safety comparing prefilled syringe and autoinjector administration.
Study Type: Phase 1 randomized bioequivalence study
Population: 241 healthy adults
Intervention: 250 mg lebrikizumab subcutaneously via PFS-NSD or autoinjector
Outcomes: PK parameters (AUC, Cmax), safety
Key Findings
- Bioequivalence confirmed between devices; PK ratios within 0.80-1.25
- No impact of injection site (abdomen, arm, thigh) on exposure
- No serious adverse events; favorable tolerability
Context & Related Research
- Detke HC et al., 2018: No PK differences between autoinjector and syringe for galcanezumab, autoinjector favored for ease (PMID:30271122), supporting device acceptability.
- FDA, 2024: Lebrikizumab safety profile consistent across devices; approved dosing supports both options, facilitating patient choice.
- Simpson EL et al., 2024: Stable long-term response with lebrikizumab via PFS or autoinjector in AD patients (PMID:39123054); emphasizes importance of device training.
- Datta-Mannan A et al., 2025: Current study establishes device bioequivalence and safety, confirming interchangeable delivery methods.
Clinical Implications
- Autoinjectors provide flexible and user-friendly options comparable to prefilled syringes.
- Device choice can be individualized based on patient preferences and abilities.
- Injection site selection does not affect systemic drug exposure.
Strengths & Limitations
| Strengths | Limitations |
|---|---|
| Randomized design with robust PK analysis | Healthy volunteers; limited direct AD patient data |
| Multiple injection site evaluation | Single-dose administration only |
Conclusion
Lebrikizumab shows bioequivalent pharmacokinetics and comparable tolerability using prefilled syringe or autoinjector, supporting both for atopic dermatitis treatment.
Listen to the Podcast
Audio content available at the link below
Future Directions
Real-world adherence and usability studies comparing devices in AD patients are needed, along with mechanistic studies on injection-site effects.
